

-80-

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human Ets-2, wherein said antisense compound specifically
5 hybridizes with and inhibits the expression of human Ets-2.
2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID
10 NO: 13, 14, 16, 19, 22, 24, 25, 27, 28, 32, 35, 38, 40, 43, 44, 11, 21, 34, 37, 41, 42 or 47.
4. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID
NO: 13, 16, 19, 27, 28, 35, 38, 40 or 43.
- 15 5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
6. The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate
20 linkage.
7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
8. The antisense compound of claim 7 wherein the
25 modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
9. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
10. The antisense compound of claim 9 wherein the
30 modified nucleobase is a 5-methylcytosine.
11. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

-81-

12. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. The composition of claim 12 further comprising a colloidal dispersion system.

5 14. The composition of claim 12 wherein the antisense compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of Ets-2 in human cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that
10 expression of Ets-2 is inhibited.

16. A method of treating a human having a disease or condition associated with Ets-2 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that
15 expression of Ets-2 is inhibited.

17. The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.

18. The method of claim 17 wherein the hyperproliferative disorder is cancer.

20 19. The method of claim 16 wherein the disease or condition is a skeletal disorder.